

Please fax both pages of completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form  
Ocrevus® (ocrelizumab)



Four simple steps to submit your referral.

# 1 Patient Information



Please attach copies of front and back of the patient's medical and prescription insurance cards.

New patient  Current patient

Patient's first name \_\_\_\_\_ Last name \_\_\_\_\_ Middle initial \_\_\_\_\_

Male  Female Last 4 digits of SSN \_\_\_\_\_ Date of birth \_\_\_\_\_

Street address \_\_\_\_\_ Apt # \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Home phone \_\_\_\_\_ Cell phone \_\_\_\_\_ E-mail address \_\_\_\_\_

Parent/guardian (if applicable) \_\_\_\_\_

Home phone \_\_\_\_\_ Cell phone \_\_\_\_\_ E-mail address \_\_\_\_\_

Alternate caregiver/contact \_\_\_\_\_

Home phone \_\_\_\_\_ Cell phone \_\_\_\_\_ E-mail address \_\_\_\_\_

OK to leave message with alternate caregiver/contact

Patient's primary language:  English  Other If other, please specify \_\_\_\_\_

# 2 Prescriber Information

All fields must be completed to expedite prescription fulfillment.

Date \_\_\_\_\_ Time \_\_\_\_\_ Date medication needed \_\_\_\_\_

Prescriber's first name \_\_\_\_\_ Last name \_\_\_\_\_

Prescriber's title \_\_\_\_\_ If NP or PA, under direction of Dr. \_\_\_\_\_

Office address \_\_\_\_\_

Office contact and title \_\_\_\_\_

Office contact phone number \_\_\_\_\_ Office contact e-mail \_\_\_\_\_

Office/Infusion clinic name \_\_\_\_\_ Office/Infusion clinic affiliation \_\_\_\_\_

Street address \_\_\_\_\_ Suite # \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_ NPI # \_\_\_\_\_ License # \_\_\_\_\_

Note: Check the appropriate shipment options in Section 4: Prescribing Information.

# 3 Clinical Information

Primary ICD-10 code: \_\_\_\_\_ Laboratory results: LEVF \_\_\_\_\_ Date \_\_\_\_\_

Platelets \_\_\_\_\_ Date \_\_\_\_\_ ANC \_\_\_\_\_ Date \_\_\_\_\_

Pregnancy test \_\_\_\_\_ (+/-) Date \_\_\_\_\_ Bilirubin \_\_\_\_\_ mg/dL Date \_\_\_\_\_

FIRST TWO LOADING DOSES COMPLETED  Yes  No Note: Ocrevus loading doses must be administered in a controlled setting.

EXPECTED DATE OF FIRST/NEXT INFUSION \_\_\_\_\_

NKDA  Known drug allergies \_\_\_\_\_

Concurrent meds \_\_\_\_\_

Patient's first name \_\_\_\_\_ Last name \_\_\_\_\_ Middle initial \_\_\_\_\_ Date of birth \_\_\_\_\_

Prescriber's first name \_\_\_\_\_ Last name \_\_\_\_\_ Phone \_\_\_\_\_

# 4 Prescribing Information

**\*Provide address for the selected shipment option.  
Check Unknown if assistance is needed to identify infusion site.**

Medication	Dose	Directions	Quantity/Refills	Ship to*:
<input type="checkbox"/> Ocrevus® (ocrelizumab) Initial dose (two infusions) Note: Loading doses must be administered in a controlled infusion site.	300mg/10mL SDV Vials are diluted in NS to a final concentration of 1.2mg/mL	<b>Infusion 1:</b> 300mg in 250mL of 0.9% NS. <b>Infusion 2 (2 weeks later):</b> 300mg in 250mL of 0.9% NS. Start infusion at 30mL per hour. Increase by 30mL per hour every 30 minutes. Maximum: 180mL per hour. Duration: 2.5 hours or longer.	Dispense: <input type="checkbox"/> 2 vials No refills	<input type="checkbox"/> Office <input type="checkbox"/> Infusion Clinic <input type="checkbox"/> Unknown
<input type="checkbox"/> Ocrevus® (ocrelizumab) Subsequent doses (one infusion)	300mg/10mL SDV Vials are diluted in NS to a final concentration of 1.2mg/mL	Every 6 months infuse 600mg in 500mL of 0.9% NS. Start infusion at 40mL per hour. Increase by 40mL per hour every 30 minutes. Maximum: 200mL per hour. Duration: 3.5 hours or longer.	Dispense: <input type="checkbox"/> 2 vials Refills <input type="checkbox"/> 0 <input type="checkbox"/> 1	<input type="checkbox"/> Home <input type="checkbox"/> Office <input type="checkbox"/> Infusion Clinic <input type="checkbox"/> Unknown

All Ocrevus® orders to be administered via pump and peripheral line unless otherwise instructed.

### Additional Medication and Supplies for Home Infusion

<b>Premedication Orders</b> Acetaminophen 650mg PO 30 min prior to infusion; Diphenhydramine 50mg PO 30 min prior to infusion; Methylprednisolone 100mg IV 30 min prior to infusion <input type="checkbox"/> Other _____	Send quantity sufficient for medication infusion
<b>Fluids for Reconstitution and Administration</b> 0.9% NaCl 250mL x2 (initial dose); 0.9% NaCl 500mL (maintenance dose); 0.9% NaCl Flush 10mL (3 mL pre- and post-infusion to maintain peripheral line patency)	
<b>Hypersensitivity/Anaphylaxis Orders*</b> Stop infusion. Start NS at TKO. 0.9% NaCl 100mL Medicate with: Epinephrine pen Auto-Injector 0.3mg/0.3mL IM as needed for anaphylaxis	
<input type="checkbox"/> Prescriber, please check here to authorize ancillary supplies or medical equipment necessary such as needles, syringes, etc. to administer the therapy as needed for administration	
<input type="checkbox"/> Skilled nursing visit as needed to establish venous access, administer medication and assess general status and response to therapy. *If nursing services will be required for therapy administration, the home health nurse will call for additional orders per state regulations.	

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

**By signing below, I certify that the above therapy is medically necessary. I also authorize Accredo to initiate any de minimus authorization processes from applicable health plans, if needed, including the submission of any necessary forms to such health plans, to the extent not prohibited.**

**Prescriber's signature (sign below) (Physician attests this is his/her legal signature. NO STAMPS)**

PHYSICIAN SIGNATURE REQUIRED

**SIGN HERE**

Date

Dispense as written

Date

Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.



The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. All rights in the product names, trade names or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. © 2021 Accredo Health Group, Inc. I An Express Scripts Company. All rights reserved. MSS-00040-041921 CED2823 CRP2104\_008596.1